GovChime
Notice ID: f36eb9975e5b4f928396d9d01a0415e5Special Notice

HT9426-27-NOI-049825

Active, responses due . Full description on SAM.gov.

Overview

Response deadline
1:00 PM EST
Posted
November 18, 2026
Notice type
Special Notice
NAICS
541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Agency
Department of WarDEFENSE HEALTH AGENCY (DHA)

Notice details

Office
DEFENSE HEALTH AGENCY
Place of performance
Mitochon Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA 19422-1574., Blue Bell, Pennsylvania, 19422
Last updated
Nov 18, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
HT9426-27-NOI-049825
Notice ID
f36eb9975e5b4f928396d9d01a0415e5

Description

The Defense Health Agency Contracting Activity (DHACA) on behalf of the WRAIR, CMPN, ISB, intends to negotiate on a sole source basis in accordance with RFO 6.103 with vendor Mitochon Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA 19422-1574. The contractor shall supply two (2) Batches of the proprietary prodrug MP201 to ISB for testing Acute Stress Reactions (ASRs). This includes providing quality control documentation and dosage background information. Additionally, the contractor shall provide informational support to the ISB research team by assisting with preparing reports and manuscripts related to MP201. Each batch of synthesized MP201 shall consist of a freshly made lot of prodrug to determine target dosage in the range of approximately 8 - 80 mg/kg body weight. These doses shall be developed in quantities to support oral administration in mice. THIS NOI IS NOT A REQUEST FOR COMPETITIVE PROPOSALS, and no solicitation document exists for this requirement. Meaningful submissions received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government.. Responsible, interested parties may identify their interest by submitting capability statements (using PDF, MS Word, or Excel attachments), in writing, by 2:00 p.m. Eastern Time, 31 December 2026 to Herbert Keen at herbert.e.keen.civ@health.mil and Mr. Lance Nowell at lance.l.nowell.civ@health.mil. Supporting evidence must be furnished in sufficient detail to demonstrate the firms ability to provide the stated capability. Information and materials submitted in response to this request WILL NOT be returned. DO NOT SUBMIT CLASSIFIED MATERIAL. Responses will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the Government. If no responses are received, the DHACA will proceed with the sole source contract issued to Mitochon Pharmaceuticals, Inc.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Documents

Files (1)

  • Notice of Intent to Sole Source - M201 ProDrug_Approved for posting 16NOV26.pdf

    126 KBAdded in Special Notice version 1Posted
    Download

Lifecycle

  1. 1
    Version 1Special Notice

    Notice of Intent (NOI) to Sole Source proprietary prodrug MP201 to ISB for testing Acute Stress Reactions (ASRs)

    Notice f9ba736f43b5425bbbcd8d523236bba8 on SAM.gov

  2. 2
    Version 2Special NoticeCurrent

    HT9426-27-NOI-049825

    Notice f36eb9975e5b4f928396d9d01a0415e5 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

HT9426-27-NOI-049825

Archive Date

Jan 18, 2027

Office Address

FORT DETRICK, MD, 21702